Webinar | November 19, 2026

Process Intensification Beyond mAbs: Advancing Perfusion Manufacturing For Cell & Gene Therapies

Source: Repligen

Upstream intensification and perfusion changed the economics of monoclonal antibody manufacturing, bringing higher productivity, better facility utilization, and lower cost of goods. Cell and gene therapy developers are now adapting those same approaches. Low yields, scale-up limits, process variability, and economic pressure remain common obstacles across lentiviral vector production, CAR-T and NK cell therapies, and iPSC-based platforms. How far the mAb experience carries over to these modalities is the open question. Recent case studies inform the discussion, which looks at perfusion culture, advanced cell retention technologies, and emerging process analytical technology (PAT) capabilities designed to support next-generation cell therapy manufacturing.

Watch to see how mAb process intensification is being applied to cell and gene therapy production.

Access The Webinar!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Bioprocess Online